If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"","arm_groups":[{"arm_group_label":"Subjects without neuropsychiatric events","arm_group_description":"Subjects without neuropsychiatric events on, DTG-based, EFV-based, RAL-based, or DRV-based regimens or FDC of emtricitabine/rilpivirine/tenofovir or FDC of elvitegravir/emtricitabine/cobicistat/tenofovir will be analyzed. Both ART naïve and ART experienced subjects will be evaluated.","arm_type":""},{"arm_group_label":"Subjects with neuropsychiatric events","arm_group_description":"Subjects with neuropsychiatric events on, DTG-based, EFV-based, RAL-based, or DRV-based regimens or FDC of emtricitabine/rilpivirine/tenofovir or FDC of elvitegravir/emtricitabine/cobicistat/tenofovir will be analyzed. Both ART naïve and ART experienced subjects will be evaluated.","arm_type":""}],"assignment":"","brief_summary":"The objective of the study is to summarize neuropsychiatric tolerability diagnoses in a population of human immunodeficiency virus (HIV)-positive males and females who have been prescribed dolutegravir (DTG) including both antiretroviral therapy (ART) naïve and ART experienced patients. A descriptive analysis of neuropsychiatric diagnoses made within a large, geographically-diverse, real-world clinical setting utilizing prospectively-collected electronic medical record (EMR) data obtained from the Observational Pharmaco-Epidemiology Research & Analysis (OPERA, trade name owned by Epividian, Healthcare Analytics and Software firm)® Observational Database will be performed.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"PRJ2693: Descriptive Analysis of Neuropsychiatric Diagnoses in Patients taking Dolutegravir in the OPERA® Observational Database","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 21:18:30","criteria":"Inclusion Criteria: - Treatment naïve and treatment experienced subjects with HIV infection - Subjects on DTG-based, EFV-based, RAL-based, or DRV-based regimens or FDC of emtricitabine/rilpivirine/tenofovir or FDC of elvitegravir/emtricitabine/cobicistat/tenofovir Exclusion Criteria: - No criteria","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"","display_phase_internal":"","display_status":"Planned","display_status_internal":"RECSTATUS_O_PLANNED","endpoint":"","enrollment":"1","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"None","id":"7b594985-7003-5ed6-a3f3-15705fbae1bc","internal":{"content":null,"contentDigest":"230b2f154bbc86cfd4d96b7e0ce6fb44","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Treatment naïve and treatment experienced subjects with HIV infection - Subjects on DTG-based, EFV-based, RAL-based, or DRV-based regimens or FDC of emtricitabine/rilpivirine/tenofovir or FDC of elvitegravir/emtricitabine/cobicistat/tenofovir Exclusion Criteria: - No criteria","interventions":[{"arm_group_label":"Subjects without neuropsychiatric events","intervention_description":"It can be as a single agent tablet or FDC regimen dolutegravir /abacavir/lamivudine.","intervention_name":"Dolutegravir-based regimen","intervention_type":"drug"},{"arm_group_label":"Subjects with neuropsychiatric events","intervention_description":"It can be as a single agent tablet or FDC regimen dolutegravir /abacavir/lamivudine.","intervention_name":"Dolutegravir-based regimen","intervention_type":"drug"},{"arm_group_label":"Subjects without neuropsychiatric events","intervention_description":"It can be as a single agent tablet or multiple drug therapy","intervention_name":"Darunavir-based regimens","intervention_type":"drug"},{"arm_group_label":"Subjects with neuropsychiatric events","intervention_description":"It can be as a single agent tablet or multiple drug therapy","intervention_name":"Darunavir-based regimens","intervention_type":"drug"},{"arm_group_label":"Subjects without neuropsychiatric events","intervention_description":"It is a fixed dose combination","intervention_name":"Elvitegravir/emtricitabine/cobicistat/tenofovir FDC","intervention_type":"drug"},{"arm_group_label":"Subjects with neuropsychiatric events","intervention_description":"It is a fixed dose combination","intervention_name":"Elvitegravir/emtricitabine/cobicistat/tenofovir FDC","intervention_type":"drug"},{"arm_group_label":"Subjects without neuropsychiatric events","intervention_description":"It is a fixed dose combination","intervention_name":"Emtricitabine/rilpivirine/tenofovir fixed dose combination (FDC)","intervention_type":"drug"},{"arm_group_label":"Subjects with neuropsychiatric events","intervention_description":"It is a fixed dose combination","intervention_name":"Emtricitabine/rilpivirine/tenofovir fixed dose combination (FDC)","intervention_type":"drug"},{"arm_group_label":"Subjects without neuropsychiatric events","intervention_description":"It can be as a single agent tablet or multiple drug therapy","intervention_name":"Efavirenz-based regimens","intervention_type":"drug"},{"arm_group_label":"Subjects with neuropsychiatric events","intervention_description":"It can be as a single agent tablet or multiple drug therapy","intervention_name":"Efavirenz-based regimens","intervention_type":"drug"},{"arm_group_label":"Subjects without neuropsychiatric events","intervention_description":"It can be as a single agent tablet or multiple drug therapy","intervention_name":"Raltegravir-based regimens","intervention_type":"drug"},{"arm_group_label":"Subjects with neuropsychiatric events","intervention_description":"It can be as a single agent tablet or multiple drug therapy","intervention_name":"Raltegravir-based regimens","intervention_type":"drug"}],"interventional_subtype":"","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":["Human Immunodeficiency Virus","Infection","Neuropsychiatric diagnoses"],"last_follow_up_date":"07/28/2017 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"","maximum_age":null,"minimum_age":null,"minimum_age_raw":"","modified_date":"10/01/2018 22:40:48","number_of_arms":"0","observational_design":{"biospecimen_description":"","biospecimen_retention":"None retained","number_of_groups":"0","observational_study_design":"Other","patient_registry":"false","target_duration_quantity":"","target_duration_units":"","timing":"Retrospective"},"official_title":"PRJ2693: Descriptive Analysis of Neuropsychiatric Diagnoses in Patients taking Dolutegravir in the OPERA® Observational Database","org_study_id":"205846","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Not yet recruiting - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":["United States: No Health Authority"]},"phase":"","primary_compl_date":"07/28/2017 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Number of subjects having neuropsychiatric events","outcome_time_frame":"2 years 8 months","outcome_safety_issue":"True"},{"outcome_description":"","outcome_measure":"Time to discontinuation of DTG regimen","outcome_time_frame":"2 years 8 months","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Demographics of subjects on DTG having neuropsychiatric events","outcome_time_frame":"2 years 8 months","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Demographics of subjects on DTG not having neuropsychiatric events","outcome_time_frame":"2 years 8 months","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["N/A","GSK"]},"start_date":"05/18/2016 00:00:00","study_type":"Observational","therapeutic_area":"","citations":[],"is_section_801":null}},"pageContext":{"studyId":"205846"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}